Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831089 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
A Phase 1 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT01831089: Completed Phase 1 study, sponsored by PharmaMar.
NCT01831089 is a Phase 1 study that has completed, run by PharmaMar. The registered enrollment target is 69 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01831089, a Phase 1 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
Primary Outcome
The MTD will be the lowest level at which one third or more evaluable patients experience a DLT in Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
Interventions
- DRUG PM01183 + paclitaxel +/- bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
What the finished NCT01831089 record still lists
NCT01831089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 1 intervention - of which PM01183 + paclitaxel +/- bevacizumab is the first listed.
NCT01831089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01831089 about?
NCT01831089 is a clinical study titled "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors". Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
What is the current status of trial NCT01831089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2013-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01831089?
The interventions under investigation include: PM01183 + paclitaxel +/- bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01831089?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01831089's enrollment target sits among peer trials
69 774th of 2000 higher than 1,225 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia